Atypical antipsychotic drugs: Current issues of safety and efficacy in the management of schizophrenia

Current Opinion in Investigational Drugs

Volumn 8, Issue 7, 2007, Pages 531-538

  Vohora, D ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Atypical antipsychotic; Cognition; Depression; Extrapyramidal symptom; Hyperprolactinemia; Mania; Metabolic effect; Negative symptom; QT interval

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MOLINDONE; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

AKATHISIA; AMENORRHEA; ANXIETY DISORDER; BIPOLAR DEPRESSION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSLIPIDEMIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GYNECOMASTIA; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPOMANIA; INFERTILITY; MANIA; METABOLIC SYNDROME X; NEGATIVE SYNDROME; OBESITY; PARKINSONISM; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TORSADE DES POINTES; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; DRUG TOXICITY; HUMANS; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34347344910     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Lublin H, Eberhard J, Levander S: Current therapy issues and unmet clinical needs in the treatment of schizophrenia: A review of the new generation antipsychotics. Int Clin Psychopharmacol (2005) 20(4):183- 198. • A thorough discussion of the clinical issues related to the use of atypical antipsychotics.
2. Murphy BP, Chung YC, Park TW, McGorry PD: Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res (2006) 88(1-3):5-25. • A comprehensive review of the direct and indirect effects of atypical antipsychotics on the negative symptoms of schizophrenia. In addition, the pharmacological interventions available for the undifferentiated negative symptoms are discussed.
3. King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (1998) 8(1):33-42.
4. Carta MG, Hardoy MC, Dellosso L, Carpiniello B: Tardive dyskinesias: Review of the literature. Clin Ther (2004) 155(4):127-133.
5. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinemia: Mechanisms, clinical features and management. Drugs (2004) 64(20):2291-2314. •• A 'must-read' review of the mechanisms and management of antipsychoticinduced hyperprolactinemia.
6. Otani K, Kondo T, Kaneko S, Ishida M, Fukushima Y: Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. Int Clin Psychopharmacol (1994) 9(4):287-289.
7. Murdoch D, Keating GM: Sertindole, a review of its use in schizophrenia. CNS Drugs (2006) 20(3):233-255.
8. Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C: Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psych (2007) 31(1):92-96.
9. Miller KK: Management of hyperprolactenemia in patients receiving antipsychotics. CNS Spectr (2004) 9(8 Suppl 7):28-32.
10. Kapur S, Lecrubier Y (Eds): Dopamine in the Pathophysiology and Treatment of Schizophrenia. Taylor & Francis, London, UK (2005).
11. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical antipsychotic trials of intervention effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 353(12):1209-1223.
12. Tarsy D, Baldessarini RJ, Tarazi FI: Effects of newer antipsychotics on extrapyramidal function. CNS Drugs (2003) 17(4):202.
13. Reynolds C, Kilpatrick AT, Bratty R: Zotepine, a broad spectrum antipsychotic with low extrapyramidal side effects. European Neuropsychopharmacology (1997) 7(Suppl 2):S225.
14. Meltzer HY: What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol (2004) 4(1):53-57. • The atypicality of antipsychotics with respect to their effects on EPS and cognitive function is discussed, along with the neurochemical basis of these effects.
15. Chakraborty N, Johnston T: Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol (2004) 19(6):351-353.
16. Abu-kishk I, Toledano M, Reis A, Daniel D, Berkovich M: Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol 42(6):921-925.
17. Leibold J, Patel V, Hasan RA: Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther (2004) 26(7):1105-1108.
18. McKaeage K, Plosker GL: Amisulpride: A review of its use in the management of schizophrenia. CNS Drugs (2004) 18(13):933-956.
19. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacol (2006) 31(9):1991-2001.
20. Casey DE: Metabolic issues and cardiovascular diseases in patients with psychiatric disorders. Am J Med (2005) 118(Suppl 2):S155-S225. • The metabolic issues associated with antipsychotic treatment are described.
21. De Hert M, van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol (2006) 21(Suppl 2):S11-S15.
22. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T: Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psych Res (2003) 37(3):193-220.
23. Nasrallah H: A review of effect of atypical antipsychotics on weight. Psychoneuroendocrinology (2003) 28(Suppl 1):S83-S96.
24. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry (1999) 156(11):1686-1696.
25. Curzon G, Gibson EL, Oluyomi AO: Appetite suppression by commonly used drugs depends on 5HT receptors but not on 5HT availability. Trends Pharmacol Sci (1997) 18(1):21-25.
26. Kraus T, Haack M, Schuld A, Hinez-Selch D, Kuhn M, Uhr M, Pollmacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry (1999) 156(2):312-314.
27. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs (2005) 19(Suppl 1):S1-S93.
28. Gury C: Schizophrenia, diabetes mellitus and antipsychotics. Encephale (2004) 30(4):382-389.
29. Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. Can J Psychiatry (2006) 51(8):480-491.
30. Wetterling T: Hyperlipidemia - side-effect of the treatment with an atypical antipsychotic (zotepine)? Psych Prax (2002) 29(8):438-440.
31. Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr Res 70(1):1-17.
32. Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol (2001) 21(4):369-374.
33. Lindstrom E, Farde L, Eberhard J, Haverkamp W: QTc interval prolongation and antipsychotic drug treatments: Focus on sertindole. Int J Neuropsychopharmacol (2005) 8(4):615-629.
34. Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W, Lader M, Moore N: Atypical antipsychotics, from potassium channels to torsades de pointes and sudden death. Drug Saf (2005) 28(1):35-51.
35. Goodnick PJ, Jerry JM: Aripiprazole: Profile on efficacy and safety. Expert Opin Pharmacother (2002) 3(12):1773-1781.
36. Finzel M, Fric M, Launx G: QT interval prolongation in therapy with atypical antipsychotics - results of an open, non-randomized survey. Psych Prax (2004) 31(Suppl 1):S178-S180.
37. Michalopoulou PG, Lykouras L: Manic/hypomanic symptoms induced by atypical antipsychotics: A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30(4):549-564. • A rare insight into the effects of antipsychotics on mania.
38. Tandon R: Safety and tolerability: How do the newer generation 'atypical' antipsychotics compare? Psychiatr Q (2002) 73(4):297-311.
39. Kasper S, Resinger E: Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology (2003) 28(Suppl 1):S27-S38.
40. Gallhofer B, Bauer U, Lis S, Krieger S, Groppe H: Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol (1996) 6(Suppl 2):S13-S20.
41. 1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J Neurochem (2006) 96(3):853-860.
42. 1A agonist interactions. Eur Neuropsychopharmacol (2006) 16(Suppl 4):178-179.
43. Stip E, Chouinrd S, Boulay LJ: On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psych (2005) 29(2):219-232.
44. Barbee JG, Conrad EJ, Jamhour NJ: The effectiveness of olanzapine, risperidone, quetiapine and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psych (2004) 65(7):975-981.
45. Brugue E, Vieta E: Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psych (2007) 31(1):275-280.
46. McCormack PL, Wiseman LR: Olanzapine: A review of its use in the management of bipolar I disorder. Drugs (2004) 64(23):2709- 2726.
47. Surja AA, Tamas RL, El-Mallakh R: Antipsychotic medications in the treatment of bipolar disorder. Curr Drug Targets (2006) 7(9):1217-1224.
48. Carson WH, Kitagawa H: Drug development for anxiety disorders: New roles for atypical antipsychotics. Psychopharmacol Bull (2004) 38(Suppl 1):S38-S45.
49. Gao K, Muzina D, Gaiwani P, Calabrese JR: Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review. J Clin Psychiatry (2006) 67(9):1327-1340.